Clene Inc. (NASDAQ: CLNN) has Emerged as a Leader in the Neurodegenerative Field Utilizing a Novel Nanotherapeutic Drug
Clinical trials of Clene’s lead candidate CNM-Au8(R) have shown notable success in crossing the blood-brain barrier and enhancing the brain's bioenergetic metabolites, essentially "reversing the clock" on what would be considered healthy aging CNM-Au8 has shown promise in clinical trials for both ALS and MS, including improvements in survival rates and clinical function Clene was recently featured in an interview of CEO Rob Etherington on ‘First in Human’ podcast In a significant advancement for the treatment of neurodegenerative diseases, Clene (NASDAQ: CLNN) has innovated CNM-Au8, an oral nanotherapeutic designed to revitalize the brain's mitochondrial function. The potential of this drug…